Boy, was I wrong about Dendreon, analyst says

It isn't often that a Wall Street analyst admits to a mistake. But ISI Group's Mark Schoenebaum not only says he was wrong to be so optimistic about Dendreon ($DNDN) and its struggle to sell the prostate cancer treatment Provenge, he called it "the worst call of my 13 year career." Report